S

Stoke Therapeutics
D

STOK

10.270
USD
0.25
(2.50%)
مفتوح الان
حجم التداول
7,993
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
543,970,854
الأخبار المقالات

العنوان: Stoke Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.